Novavax on Thursday tried to calm investors spooked by the delay of full approval of its COVID vaccine shot by U.S.

Novavax Inc. (NASDAQ:NVAX) reported first-quarter 2025 sales of $667 million, compared to $94 million a year ago, beating the ...

Novavax is undervalued, presenting an attractive risk-reward profile for long-term investors. Click here to find out why NVAX ...

Vaccine maker Novavax is seeking to convert the 2022 emergency authorization of its Covid-19 vaccine into full approval. Yet ...

Novavax said on Thursday discussions with the U.S. health regulator on its COVID-19 shot are ongoing and a pathway to ...

Dr. Marty Makary, chief of the FDA, has expressed doubts about the agency approving the COVID-19 vaccine for winter, stating ...

An FDA committee will soon make recommendations about this fall’s Covid-19 vaccines while Novavax still awaits full FDA ...

Yes, according to leading vaccine physician Paul Offit, who denounced the new placebo-controlled trial requirements for ...

The company is focused on optimizing its partnership with Sanofi, which includes potential milestones and royalties from new combination vaccines. Novavax Inc (NASDAQ:NVAX) is advancing its early ...

Also Read: Trump-Era FDA Appointees Request New Trials For Novavax COVID Vaccine, Reportedly Delaying Approval Timeline The COVID-19 vaccine maker reported an earnings per share of $2.93 ...

The company wants to convert the vaccine's emergency authorization granted in 2022 into a full approval that would allow for expanded use and help it compete against shots from rivals. Novavax ...